Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2026-02-26 @ 2:19 AM
Study NCT ID:
NCT02495233
Status:
TERMINATED
Last Update Posted:
2024-11-27
First Post:
2015-07-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
2215-CL-5101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None